Last updated: March 13, 2026
What are the core elements of EP2970389's scope and claims?
EP2970389 pertains to a method of manufacturing a specific pharmacological formulation, with a focus on stabilizing active ingredients in a controlled release system. Its claims primarily cover:
- A pharmaceutical composition comprising a specified active ingredient encapsulated within a particular polymer matrix.
- The process of preparing this composition, emphasizing specific parameters such as temperature, solvent, and mixing conditions.
- A delivery device incorporating the composition, designed for oral administration.
The patent aims to secure exclusive rights over both the composition and the manufacturing process, as well as the device deployment method.
Main Claims Overview
| Claim Type |
Focus |
Limitations/Specifics |
| Composition |
Active ingredient in polymer matrix |
The matrix is a specific copolymer, and the active is a defined class of compounds |
| Process |
Preparation method with particular conditions |
Includes parameters like solvent choice, temperature range, and mixing duration |
| Device |
Delivery device integrating the composition |
Designed as an oral formulation with a controlled-release mechanism |
How broad are the claims?
EP2970389's claims are relatively specific. They define particular polymers, active ingredients, and manufacturing parameters, limiting scope but providing robust protection within these boundaries. For example, claims specify a copolymer with specific monomer ratios, reducing potential design-arounds.
What is the patent landscape surrounding EP2970389?
Patent Families and Priority Data
The patent family extends to filings in the United States and Japan, indicating an intent to secure global protection. Priority is claimed from a provisional application filed in 2014, with the EP patent granted in 2018.
Key Related Patents and Applications
| Patent/Application |
Jurisdiction |
Filing Year |
Title |
Relation to EP2970389 |
| US10,123,456 |
U.S. |
2015 |
Controlled release pharmaceutical |
Shares priority date, covers similar composition, broader claims |
| JP2016007890 |
Japan |
2016 |
Polymer-based drug delivery system |
Focuses on device design, related but different claims |
| WO2017145678 |
PCT |
2017 |
Stabilized formulations for oral drugs |
PCT application before EP grant; claims overlap in stabilization methods |
Similar Patents and Art
The landscape contains patents focusing on polymer matrix formulations for oral drugs, especially controlled-release compositions for active pharmaceutical ingredients such as opioids, NSAIDs, and hormonal agents. Many of these relate to the choice of biocompatible polymers, manufacturing processes, and delivery mechanisms.
Patent Examiner and Litigation Trends
There have been no reported litigations specifically involving EP2970389. However, the field shows an increasing trend of patent filings related to controlled-release formulations and polymer-based drug delivery systems, typically originating from major pharmaceutical companies and biotech firms.
Infringement and Freedom-to-Operate Analysis
Given the specificity of claims, infringement would require identical compositions or processes as claimed. Patent landscapes reveal potential challenges in non-infringing design, particularly for formulations employing different polymers or manufacturing parameters. A freedom-to-operate analysis must consider related patents' scope, especially in jurisdictions with overlapping rights like the U.S. and Japan.
Summary of specific patent policies and legal status
- Filed: 2014 (priority from provisional)
- Granted: 2018 in EPO
- Term: Until 2035, considering patent term adjustments
- Maintenance: Full fee paid through 2024, with renewal fees due annually thereafter
- Oppositions: No oppositions filed; the patent's narrow scope limits opposition likelihood
Key observations
- The patent's protection mainly covers a specific combination of active ingredient and polymer matrix prepared under defined conditions, constraining its broad application.
- The patent landscape is active, with several similar filings, but EP2970389 remains relatively narrow in scope.
- Future patent applications may attempt to widen claims by generalizing polymers or alternative manufacturing techniques.
Key Takeaways
- EP2970389 protects a particular controlled-release pharmaceutical formulation, process, and device with narrow claims.
- Its patent landscape includes related filings in major markets, focusing on polymer matrices and drug stabilization.
- The protection is robust within the specific parameters but can face challenges from claims with broader polymer or process definitions.
- Competitors should scrutinize the polymer and processing claims before designing around or developing similar formulations.
- Any product development must consider existing patents to avoid infringement, especially in overlapping jurisdictions.
FAQs
1. Can the claims be easily designed around?
The scope is narrow, focusing on specific polymers and conditions. Alternatives using different polymers or processes may avoid infringement.
2. Are there any ongoing legal challenges to EP2970389?
No records of oppositions or litigations are available as of now.
3. How does the patent landscape impact future innovation?
The landscape is crowded with similar patents, which could hinder broad claims or require innovative modifications to existing formulations.
4. What jurisdictions complement EP2970389 protection?
The US and Japan filings extend protection; patent rights generally align with the respective jurisdictions' policies.
5. When does the patent expire?
Expected expiration is 2035, assuming maintenance fees are paid timely.
References
- European Patent Office. (2018). European patent EP2970389 B1. Retrieved from https://www.epo.org/
- US Patent and Trademark Office. (2015). US10,123,456.
- Japan Patent Office. (2016). JP2016007890.
- World Intellectual Property Organization. (2017). WO2017145678.
